

ALAPIS S.A.

Greece, Health, Pharmaceuticals

May 29, 2008

Company Description

Alapis Group is primarily active in 2 major strategic business units:

I. Healthcare: Pharmaceuticals,

Medical Devices & Equipment,

Veterinary Pharmaceuticals and II. Non-Healthcare: Detergents &

Cosmetics, and Organic Products.

Share Data

Price (€) 27/05/2008	2.01
# of shares (M.)	980.6
Capitalization (M €)	1,971
ATHEX	ALAPIS
REUTERS	ALAr.AT
BLOOMBERG	ALAPIS_GA
ISIN	GRS 322003013

Pro Forma Figures

P&L HIGHLI	GHTS	FY 2005	FY 2006	FY 2007
SALES	(000 €)	180,120	273,456	472,746
EBITDA	(000 €)	25,847	46,107	123,644
EATAM	(000 €)	-9,399	20,095	87,465
RATIOS		FY 2005	FY 2006	FY 2007
P/E	(x)	-209.70	98.08	22.53
P/BV	(x)	11.39	2.67	1.22
EV/EBITDA	(x)	79.78	45.16	14.11

Investment ratios computed at share price 2.01 (27/05/2008) and no. of shares 980,600,220.

The above results are not comparable with the equivalent results of the respective period of 2006, as they do not include the absorbed companies.

Key Developments

In Q1 2008, ALAPIS Group of Companies turnover amounted to EUR 208.1 mil., significantly increased by 320.3% over Q1 2007, while consolidated EBITDA stood at EUR 57.6 mil. increased by 360% and earnings after tax and minorities reported at EUR 33.3 mil. up by 350.3% over the respective period last year.

Q1 2008 results have been significantly increased because of both the consolidation in this quarter of all acquired companies and the organic growth of the Group in all sectors.

Healthcare division

Healthcare division (human and Veterinary) turnover amounted to EUR 169.0 mil while EBITDA stood at EUR 46.9 mil.

Non-healthcare division

Non-healthcare division (Detergents – Cosmetics and Organic products) turnover totaled EUR 39.1 mil. while EBITDA reached EUR 10.7 mil.

Financial Guidance for 2008

FY 2008(e): Turnover: EUR 900 mil., EBITDA EUR 250 mil. and earnings after tax and minority rights EUR 160 mil.

Q1 Financial Results

(FY: December) (M €)	Q1 2007	Q1 2008	Δ (%)
Sales	49.5	208.1	320.3%
Gross Profit	18.2	64.7	255.4%
EBITDA	12.5	57.6	360.0%
EBIT	10.5	43.1	309.9%
EBT	9.3	40.4	333.5%
EAT & Minorities	7.4	33.3	350.3%
Margin Analysis %	Q1 2007	Q1 2008	
Gross Profit	36.8%	31.1%	
EBITDA	25.3%	27.7%	
EBIT	21.2%	20.7%	
EBT	88.6%	19.4%	
EAT & Minorities	14.9%	16.0%	

Reclassifications have been made in Q1 2007 figures due to the finalization of the goodwill of the merger

Consolidated Income Statement

(FY: December) (000 €)	Q1 2007	Q1 2008
Sales	49,511	208,091
Cost of Goods Sold	-31,301	-143,371
Gross Profit	18,210	64,720
Other Revenues-(Expenses)	472	3,561
SG&A Expenses	-8,169	-25,186
EBITDA	12,523	57,603
Depreciation	-2,009	-14,508
EBIT	10,514	43,095
Total Financial Results	-1,194	-2,694
EBT	9,319	40,401
Taxation	-1,920	-7,140
Minorities	0	-54
EAT & Minorities	7,399	33,314

Margin Analysis %	Q1 2007	Q1 2008
Gross Profit	36.8%	31.1%
SG&A Expenses	16.5%	12.1%
EBITDA	25.3%	27.7%
EBIT	21.2%	20.7%
ЕВТ	18.8%	19.4%
EAT & Minorities	14.9%	16.0%
Period / Period %	Q1 2007	Q1 2008


Period / Period %	Q1 2007	Q1 2008
Sales		320.3%
Gross Profit		255.4%
SG&A Expenses		208.3%
EBITDA		360.0%
EBIT		309.9%
EBT		333.5%
EAT & Minorities		350.3%
	04 0007 6	


Reclassifications have been made in Q1 2007 figures due to the finalization of the goodwill of the merger


Consolidated Balance Sheet


(in 000. €)	FY 2007	Q1 2008
ASSETS		
Non-current Assets		
Tangible Assets	523,335	556,37
Intangible Assets	754,987	887,42
Other long-term assets	22,780	3,21
Deferred income taxes	11,068	12,2
Total Non-Current Assets	1,312,170	1,459,28
Current Assets		
Inventories	119,499	145,62
Trade accounts receivables	18,165	103,5
Other current assets	62,084	82,4
Cash and Cash equivalents	318,023	217,8
Total Current Assets	517,771	549,47
TOTAL ASSETS	1,829,942	2,008,76
EQUITY & LIABILITIES		
Share Capital	294,180	294,18
Paid-in surplus	1,177,497	1,177,46
Adjustment's differences and other reserves	92,986	93,38
Retained earnings	44,817	52,9
Minority interests	0	81
Total Equity	1,609,480	1,618,85
Non-Current Liabilities		
Long-term borrowings at amortised cost	62,052	155,00
Deffered Tax Liabilities	14,896	17,8
Provisions for dismissal indemnities	4,134	5,10
Other long-term Liabilities	21,143	18,89
Total Non-Current Liabilities	102,224	196,91
Current Liabilities		
Trade accounts payable	39,660	104,3
Short-term borrowings	29,570	11,2
Income taxes payable	15,975	26,7:
Accrued and other current liabilities	33,032	50,68
Total Current Liabilities	118,237	192,99
TOTAL LIABILITIES & EQUITY	1,829,942	2,008,76

goodwill of the merger









This presentation contain forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Further details of potential risks and uncertainties affecting ALAPIS Group are described in the ALAPIS's filings with the Athens Stock Exchange. These forward-looking statements speak only as of the date of this